Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) lower blood pressure (BP). When SGLT2i and GLP-1RA are combined, synergistic effects on BP have been observed. The mechanisms underlying these BP reductions are incompletely underst...

Descripción completa

Detalles Bibliográficos
Autores principales: van Ruiten, Charlotte C., Smits, Mark M., Kok, Megan D., Serné, Erik H., van Raalte, Daniël H., Kramer, Mark H. H., Nieuwdorp, Max, IJzerman, Richard G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052512/
https://www.ncbi.nlm.nih.gov/pubmed/35484607
http://dx.doi.org/10.1186/s12933-022-01492-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052512/
https://www.ncbi.nlm.nih.gov/pubmed/35484607
http://dx.doi.org/10.1186/s12933-022-01492-x

Ejemplares similares